{"id":"xydalba","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01946568","NCT02940730","NCT04624451","NCT01431339","NCT02344511","NCT06423898","NCT04847921","NCT04485676","NCT06266494","NCT00057369","NCT06899906","NCT01339091","NCT05046860","NCT03233438","NCT04775953","NCT03148756","NCT04959799","NCT05977868","NCT03372941","NCT03941951","NCT02814916","NCT04298463","NCT03091439","NCT06089044","NCT06688084","NCT03982030","NCT03426761","NCT03696901","NCT02688790","NCT02685033","NCT05117398","NCT00678106","NCT06810583","NCT02269644","NCT03726216","NCT02961764","NCT02127970"],"aliases":["Dalbavancin","Dalbavancine"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Xydalba","companyId":"correvio-international-sarl","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Correvio International Sarl","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Xydalba","indications":{"approved":[{"name":"Bacterial infection of skin","diseaseId":"bacterial-infection-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of skin AND/OR subcutaneous tissue","diseaseId":"infection-of-skin-and/or-subcutaneous-tissue","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal infection of skin","diseaseId":"staphylococcal-infection-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01946568","phase":"Phase 1","title":"A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous A","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":false,"enrollment":36,"indication":"Bacterial Infections.","completionDate":"2015-04"},{"nctId":"NCT02940730","phase":"Phase 4","title":"Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":10,"indication":"Infectious Peritonitis","completionDate":"2018-06-18"},{"nctId":"NCT04624451","phase":"N/A","title":"Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":2,"indication":"Peritonitis, Peritonitis Bacterial","completionDate":"2024-01-31"},{"nctId":"NCT01431339","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin a","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":true,"enrollment":739,"indication":"Abscess, Wound Infection","completionDate":"2012-12"},{"nctId":"NCT02344511","phase":"Phase 3","title":"A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyel","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","isPivotal":true,"enrollment":0,"indication":"Osteomyelitis","completionDate":"2019-04"},{"nctId":"NCT06423898","phase":"Phase 4","title":"Efficacy and Safety of Ampicillin and Ceftriaxone Continuous Infusion Versus Standard Therapy for the Treatment of Enterococcus Faecalis Infective Endocarditis (DOβLEI Study)","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","isPivotal":false,"enrollment":284,"indication":"Endocarditis, Infective","completionDate":"2028-12-31"},{"nctId":"NCT04847921","phase":"Phase 2","title":"Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections","status":"TERMINATED","sponsor":"University of Colorado, Denver","isPivotal":true,"enrollment":11,"indication":"Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia","completionDate":"2023-10-05"},{"nctId":"NCT04485676","phase":"N/A","title":"Dalbavancin in Real Clinical Practice in Spain: a Two-year Retrospective Study","status":"COMPLETED","sponsor":"Angelini Farmacéutica","isPivotal":false,"enrollment":187,"indication":"Skin Diseases, Bacterial, Skin Diseases, Infectious","completionDate":"2021-02-21"},{"nctId":"NCT06266494","phase":"Phase 4","title":"Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis","status":"RECRUITING","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":100,"indication":"Frostbite","completionDate":"2026-08"},{"nctId":"NCT00057369","phase":"Phase 2","title":"Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or ","status":"UNKNOWN","sponsor":"Vicuron Pharmaceuticals","isPivotal":false,"enrollment":88,"indication":"Bacteremia","completionDate":"2003-06"},{"nctId":"NCT06899906","phase":"N/A","title":"Efficacy and Safety of Dalbavancin As Suppressive Therapy","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":33,"indication":"Efficacy and Safety of Dalbavancin, In Subjects Who Received SAT with DAL","completionDate":"2025-05-01"},{"nctId":"NCT01339091","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin ","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":true,"enrollment":573,"indication":"Abscess, Wound Infection","completionDate":"2012-11"},{"nctId":"NCT05046860","phase":"NA","title":"Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","isPivotal":false,"enrollment":43,"indication":"Osteoarticular Infection","completionDate":"2024-09-30"},{"nctId":"NCT03233438","phase":"Phase 4","title":"Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":91,"indication":"Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection","completionDate":"2018-10-30"},{"nctId":"NCT04775953","phase":"Phase 2","title":"Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbava","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":200,"indication":"Staphylococcal Bacteraemia","completionDate":"2023-12-01"},{"nctId":"NCT03148756","phase":"Phase 2","title":"Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated","status":"TERMINATED","sponsor":"AbbVie","isPivotal":false,"enrollment":2,"indication":"Endocarditis, Bacteremia","completionDate":"2017-08-04"},{"nctId":"NCT04959799","phase":"N/A","title":"Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections - DALBADIA Study","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","isPivotal":false,"enrollment":98,"indication":"Diabetes, Infection","completionDate":"2022-05-31"},{"nctId":"NCT05977868","phase":"Phase 4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial","status":"TERMINATED","sponsor":"West Virginia University","isPivotal":false,"enrollment":94,"indication":"Endovascular Infection, Bone and Joint Infection","completionDate":"2025-02-14"},{"nctId":"NCT03372941","phase":"Phase 4","title":"Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","status":"TERMINATED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":11,"indication":"Skin Infection","completionDate":"2021-10-14"},{"nctId":"NCT03941951","phase":"NA","title":"Quasi-experimental Intervention Study to Optimize the Use of New Antibiotics (Project NEW_SAFE)","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","isPivotal":false,"enrollment":900,"indication":"Bacterial Infections, Fungal Infection","completionDate":"2022-12-31"},{"nctId":"NCT02814916","phase":"Phase 3","title":"A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin ","status":"COMPLETED","sponsor":"AbbVie","isPivotal":true,"enrollment":199,"indication":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections","completionDate":"2024-01-01"},{"nctId":"NCT04298463","phase":"N/A","title":"Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","isPivotal":false,"enrollment":184,"indication":"Acute Bacterial Skin and Skin Structure Infection","completionDate":"2021-05-19"},{"nctId":"NCT03091439","phase":"Phase 2","title":"A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected t","status":"TERMINATED","sponsor":"Allergan","isPivotal":false,"enrollment":1,"indication":"Osteomyelitis","completionDate":"2017-08-31"},{"nctId":"NCT06089044","phase":"N/A","title":"Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections","status":"COMPLETED","sponsor":"Tourcoing Hospital","isPivotal":false,"enrollment":15,"indication":"Prosthesis-related Infections","completionDate":"2022-12-31"},{"nctId":"NCT06688084","phase":"N/A","title":"Evaluation of Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","isPivotal":false,"enrollment":230,"indication":"Diabetic Foot Ulcer","completionDate":"2026-05-01"},{"nctId":"NCT03982030","phase":"Phase 4","title":"An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":0,"indication":"Gram-Positive Bacterial Infections, Soft Tissue Infections","completionDate":"2025-07"},{"nctId":"NCT03426761","phase":"Phase 4","title":"Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections","status":"COMPLETED","sponsor":"Infectious Diseases Physicians, Inc.","isPivotal":false,"enrollment":41,"indication":"Bone Infection, Osteomyelitis","completionDate":"2022-12-31"},{"nctId":"NCT03696901","phase":"N/A","title":"Xydalba Utilization Registry: A Multicenter, Prospective and Retrospective Registry to Characterize the Use of Xydalba","status":"TERMINATED","sponsor":"Correvio International Sarl","isPivotal":false,"enrollment":16,"indication":"Bacterial Infections","completionDate":"2020-04-07"},{"nctId":"NCT02688790","phase":"Phase 1","title":"Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection","status":"TERMINATED","sponsor":"AbbVie","isPivotal":false,"enrollment":8,"indication":"Bacterial Infections","completionDate":"2019-04-03"},{"nctId":"NCT02685033","phase":"Phase 2","title":"A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":false,"enrollment":80,"indication":"Osteomyelitis","completionDate":"2017-12-12"},{"nctId":"NCT05117398","phase":"Phase 3","title":"Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":true,"enrollment":406,"indication":"Catheter Bacteremia, Staphylococcus Aureus Infection","completionDate":"2026-09-23"},{"nctId":"NCT00678106","phase":"Phase 1","title":"A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenou","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":10,"indication":"Bacterial Infections","completionDate":"2009-07"},{"nctId":"NCT06810583","phase":"Phase 1","title":"A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","isPivotal":false,"enrollment":29,"indication":"Leukemia, Acute Myeloid Leukemia","completionDate":"2031-09"},{"nctId":"NCT02269644","phase":"Phase 3","title":"A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":true,"enrollment":0,"indication":"Community Acquired Pneumonia","completionDate":"2016-12"},{"nctId":"NCT03726216","phase":"N/A","title":"Observational Study on the Use of Xydalba: A Multicenter, Prospective Study to Characterize the Use of Xydalba in France","status":"COMPLETED","sponsor":"Correvio International Sarl","isPivotal":false,"enrollment":151,"indication":"Bacterial Infections","completionDate":"2020-10-28"},{"nctId":"NCT02961764","phase":"Phase 4","title":"A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":313,"indication":"Acute Bacterial Skin and Skin Structure Infections","completionDate":"2019-03-29"},{"nctId":"NCT02127970","phase":"Phase 3","title":"A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":true,"enrollment":698,"indication":"Abscess, Wound Infection","completionDate":"2015-03-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}